This resolution designates June 19, 2025 as World Sickle Cell Awareness Day to raise public awareness of sickle cell disease (SCD) and to emphasize the ongoing need for empirical research, early detection screening, new effective treatments, and preventative care programs for complications related to SCD. It also sets out concrete policy ambitions: promote equitable access to SCD therapies, spur global and domestic policy coordination, and encourage events that educate the public and stakeholders about SCD.
Beyond recognition, the measure calls for structural steps to advance access to care and to reduce disparities. It directs the Department of Health and Human Services to pursue global policy solutions that support newborn screening, therapeutic interventions, and patient services; it urges eliminating barriers to equitable access to innovative SCD therapies within Medicare and Medicaid; and it invites the President to form an interagency Sickle Cell Disease Group to coordinate policy across multiple agencies and to consider ways to address bias in healthcare systems that affect the SCD community.
At a Glance
What It Does
The resolution designates World Sickle Cell Awareness Day and articulates policy goals, including equitable access to therapies and the formation of an interagency policy group to coordinate SCD efforts.
Who It Affects
SCD patients and their families, healthcare providers, public health programs, newborn screening efforts, researchers, and federal agencies involved in health policy.
Why It Matters
It signals a coordinated approach to awareness, research, screening, and treatment access, aiming to reduce disparities and align federal actions with global SCD priorities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is a symbolic resolution, but it also sets a practical policy agenda. It designates June 19, 2025 as World Sickle Cell Awareness Day to spotlight sickle cell disease, its global impact, and the need for robust research, newborn screening, and effective treatments.
By naming this day, the measure seeks to elevate awareness among the public, health systems, and policymakers and to catalyze action across the healthcare ecosystem.
The resolution goes beyond recognition by outlining concrete aims. It calls for equitable access to novel SCD therapies—ensuring that advances in treatment are available to people regardless of income or demographic factors, and it directs the Department of Health and Human Services to develop global policy solutions that support newborn screening, therapy access, and supportive services in collaboration with other governments.
It also urges eliminating barriers to coverage for innovative therapies within Medicare and Medicaid and recommends creating an interagency Sickle Cell Disease Group to coordinate policy among key agencies, including DHHS, VA, NIH, FDA, and CMS.Finally, the bill encourages public programs and events on World Sickle Cell Awareness Day to raise awareness about SCD traits, prevention, treatments, and patient services, while pushing for ongoing attention to disparities and bias in the health system that affect those with SCD and related conditions.
The Five Things You Need to Know
The resolution designates June 19, 2025 as World Sickle Cell Awareness Day.
It commits to equitable access to SCD therapies within federal programs, prioritizing underserved populations.
It directs DHHS to develop global policy solutions for newborn screening, therapies, and supportive services.
It seeks elimination of barriers to innovative SCD therapies under Medicare and Medicaid.
It calls for the President to form an interagency Sickle Cell Disease Group to coordinate policy among multiple agencies.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Preamble and Goals
This section reiterates the resolution’s core aim: to designate World Sickle Cell Awareness Day and to articulate the overarching goals of awareness, ongoing research, and improved care for SCD. It frames the issue as a global health priority that requires sustained attention from the United States and the international community.
Equitable access to SCD therapies
This provision commits the United States to pursuing equitable access to sickle cell therapies across all economic, racial, and ethnic groups. It emphasizes reducing disparities in diagnosis, treatment, and outcomes and signals a national priority to ensure affordability and availability of emerging therapies.
Global policy solutions and domestic programs
The measure tasks the Department of Health and Human Services with creating global policy solutions that support newborn screening, therapeutic interventions, and patient services. It also urges collaboration with local governments to expand screening and treatment access and to align domestic programs with international best practices.
Eliminating access barriers in Medicare/Medicaid
This section directs efforts to remove barriers to equitable access to innovative SCD therapies, including cell- and gene-based treatments, within the Medicare and Medicaid programs. It highlights the importance of coverage decisions and streamlined access for the most vulnerable patients.
Awareness events and public engagement
The bill encourages ongoing programs, events, and activities on World Sickle Cell Awareness Day to educate the public about SCD traits, preventative care, and available therapies and services, amplifying voices within the SCD community.
Interagency SCD policy group formation
This section establishes the creation of a Sickle Cell Disease Interagency Group, comprising DHHS, the Department of Veterans Affairs, NIH, FDA, and CMS, to coordinate policy efforts, improve access to innovative therapies, and monitor implementation across agencies.
Addressing bias and access
It directs the interagency group to consider options that expand access to potential future cures while addressing persistent bias that affects the SCD population within the U.S. and global health systems. The aim is to ensure that policy changes reduce inequities and improve lived outcomes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- SCD patients and their families, who gain improved access to diagnosis, treatment, and care coordination.
- Healthcare providers and clinics who can offer consistent screening, treatment, and counseling services.
- Public health systems and newborn screening programs that expand early detection and intervention.
- SCD research communities and patient advocacy organizations that benefit from clearer policy signals and interagency collaboration.
- Federal health agencies (DHHS, NIH, FDA, CMS) that gain a coordinated framework to align initiatives.
- Global partners and low-resource health systems that can learn from U.S. and international policy alignment.
Who Bears the Cost
- Federal agencies implementing interagency coordination may require staff time and administrative resources.
- Medicare/Medicaid programs may face higher short-term costs associated with broader coverage for innovative therapies.
- State and local health departments could incur costs to expand newborn screening and patient services.
- Healthcare providers may experience transitional costs to implement new care pathways and ensure equitable access.
- Insurers and employers might adjust coverage practices as therapies become more widely available.
Key Issues
The Core Tension
Balancing ambitious, equity-focused objectives (expanded access, global collaboration, and interagency coordination) with the practical constraints of budgeting, implementation, and measurement of outcomes.
The bill advances a broad aspirational agenda rather than establishing mandatory funding or enforceable mandates. Its value lies in signaling policy priority and catalyzing cross-agency collaboration, but it relies on later action to translate these goals into concrete programs and funding streams.
A key tension is the potential gap between desire for equitable access and the fiscal and logistical realities of expanding coverage for cutting-edge therapies; another is ensuring that global policy ambitions do not outpace domestic implementation, especially for newborn screening and early intervention programs. Finally, the measure acknowledges persistent bias in health systems but does not specify enforcement mechanisms or measurable benchmarks for change.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.